Travelers Partners With Companies To Help Find Treatment For Acute Orthopedic Injuries

The Travelers Companies, Inc. (TRV) is an insurance provider of property casualty insurance for home, auto, and business.

The Travelers Companies, Inc. will be partnering with Cedars-Sinai, Samsung Electronics Americ, Bayer, and appliedVR to research the effects of therapeutic virtual reality and wearable technology as an alternative way to manage pain. They will be focusing specifically on acute orthopedic injuries of the lower back and extremities.

The clinical research project will take place at Cedars-Sinai’s Center for Outcomes Research and Education and will last over 16 months. The project will include between 90 and 140 participants with ages ranging from 18 to 65.

Workplace injuries that lead to chronic pain can cause ongoing issues, as an injured employee may mask pain with opioids or other drugs. Identifying new, non-pharmacologic alternatives for pain management can help an injured employee avoid chronic pain, lower the chances that they will develop a dangerous opioid addiction and reduce medical costs. We are grateful for this partnership and look forward to seeing the results that Dr. Brennan Spiegel and the Cedars-Sinai team uncover using the latest technology from appliedVR, Bayer and Samsung.” – said Dr. Melissa Burke, National Pharmacy Director at Travelers

To learn more about The Travelers Companies, Inc. (TRV) and to continue to track its progress please visit the Vista Partners Travelers Companies, Inc. Coverage Page.

Press Release | Travelers Insurance


Read Full Article

Caterpillar Launches Water Campaign

Caterpillar, Inc. (CAT) is the world’s chief manufacturer of diesel and natural gas engines, construction and mining equipment, industrial gas turbines, and diesel-electric locomotives. Caterpillar, Inc. works to make sustainable progress possible and contributes to driving positive change on every continent.

Water is a critical need of people and communities, yet almost 844 million people do not have access to clean, safe water.

The Caterpillar Foundation has launched the Value of Water Campaign to raise the awareness of the impact of the global water crisis on education, economics, and community health. This is one step on the foundation’s mission to help empower 50 million people globally to rise out of extreme poverty by the year 2020.

The Caterpillar Foundation will be working with multiple partners including water, Ducks Unlimited, Global Citizen, Living Land & Waters, Opportunity International, The Nature Conservancy and

Various aspects addressed in the Campaign include:

  • Bringing clean water to rural communities in Africa through construction of new wells and innovative pipe systems
  • Restoring critical wetland habitats that provide flood protection and water filtration
  • Reducing river pollution throughout the United States
  • Strengthening the health of the world’s vital rivers
  • Delivering running water to homes in Africa, Asia, and South America through micro credit loans

“As the company and its customers work to build traditional infrastructure, the Caterpillar Foundation is focused on building human infrastructure, and ultimately, a better world,” said Caterpillar Foundation President Michele Sullivan. “Water is a fundamental human need – it is a basic building block necessary to pursue opportunities such as education and economic growth, and place people on a path to prosperity.” -Michele Sullivan, Caterpillar Foundation President

To learn more about the Value of Water Campaign and how to become involved visit

To learn more about Caterpillar, Inc. (CAT) and to continue to track its progress please visit the Vista Partners Caterpillar, Inc. Coverage Page.

Caterpillar Foundation Launches Value of Water Campaign to Help its Partners Address Poverty


Read Full Article

The Dow Chemical Company Launches ECOFAST Textile Treatment

The Dow Chemical Company is a part of the DowDupont Holding Company (DWDP), a business that is focused on agriculture, materials science and specialty product sectors that will lead their respective industries through productive, science-based innovation to meet the needs of customers and help solve global challenges.

This week at the American Association of Textile Chemist and Colorists (AATCC), The Dow Chemical Company launched ECOFAST Pure Sustainable Textile Treatment. The technology in this treatment allows for unique and more vibrant colors on natural textiles and greatly improves the efficient use of resources during the dyeing process. With the new technology, fluorescents are now available for use on cotton. The treatment allows the uptake of reactive, direct, and acid dyes on natural fibers and fabrics. ECOFAST Pure also improves the color quality of a product, so that the color will last longer.

Dow has leveraged over a century of material science knowledge to help address the performance and sustainability gaps in the textile industry. By pretreating textiles with ECOFAST Pure, manufacturers can deliver longer lasting, new generation colors on natural textiles while simultaneously reducing water, dye and energy use.” – Esma Talu, market manager for Dow

To learn more about Dow and DowDuPont (DWDP) and to continue to track its progress please visit the Vista Partners DowDuPont Coverage Page.

Dow Product Enables Brighter Colors on Natural Textiles

Dow will launch ECOFAST™ Pure Sustainable Textile Treatment at the American Association of Textile Chemists and Colorists International Conference…

Read Full Article

Sonia Cargan is New Chief Diversity Officer of American Express

American Express Company (AXP), and its subsidiaries, provide customers and businesses globally with charge and credit payment card products and travel-related services. They look to enrich the lives of their customers and build business success.

Sonia Cargan has been appointed the chief diversity officer of American Express Company. With this appointment, Cargan’s job will be to ensure that American Express is an employer choice of top diverse talent and that it continues to drive unified success through a collaborative work environment and growth of inclusive teams. Cargan will also work to serve the company’s 15 colleague networks to promote a culture of inclusion and development opportunities.

Cargan received her Bachelor of Arts Honors degree in social administration from the University of Brighton and has held a 22-year career with American Express Company.

Sonia is a long-time advocate of the business results that can be achieved through the development of a diverse and inclusive organization. As an executive with a wealth of global experience, she is also ideally suited to continue to elevate and evolve our diversity and inclusion strategies through a global lens.” – Kevin Cox, chief human resources officer, American Express

To learn more about American Express Company (AXP) and to continue to track its progress please visit the Vista Partners American Express Coverage Page.

American Express Names Sonia Cargan as Chief Diversity Officer


Read Full Article

Visa Squarely Focused on Using 100% Renewable Electricity By End of 2019

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Their mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive.  Their advanced global processing network, VisaNet, provides secure and reliable payments around the world and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying their brand, products, people, network and scale to reshape the future of commerce.

Visa recently announced its commitment to using 100 percent renewable electricity across its global operations and is squarely focused accomplishing this goal by the end of 2019.  Visa is also joining the RE100 initiative, a collaborative, global platform developed by The Climate Group in partnership with CDP to increase demand for and delivery of renewable energy.

To reach 100 percent renewable electricity by the end of 2019, Visa will pursue an approach that emphasizes immediate action across its global facilities portfolio. Today, an estimated 35 percent of Visa’s global electricity consumption comes from a mix of renewable energy sources such as solar, wind, and hydropower.

Working with local utilities and competitive electricity market providers, Visa will pursue renewable electricity options available in each market that best fit its approach to renewable electricity. Visa will seek impactful, local renewable electricity investments in markets where the company has major facilities, including four locations in the U.S. and the U.K. that account for 80 percent of its global electricity use. Visa also will be transitioning the remainder of its footprint toward renewable electricity.

To learn more about Visa (V) and to track its ongoing progress please visit the Vista Partners Visa (V) Coverage Page.

Visa Commits to 100% Renewable Electricity by End of 2019

Visa today announced its commitment to using 100 percent renewable electricity across its global operations by the end of 2019…

Read Full Article

Breast Cancer Therapeutics Innovator Atossa Genetics 2017 Results & Recent Developments Highlighted

Seattle based Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.

Today Atossa announced the following recent developments:

Successful Phase 1 Study

All objectives of Atossa’s recent Phase 1 study of its proprietary oral and topical formulations of Endoxifen were successfully met: there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of Atossa’s oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen.

TRAP CAR-T Program

In October 2017, they announced that they are developing a novel method to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. This approach uses their proprietary intraductal microcatheter technology for the potential transpapillary, or “TRAP,” delivery of either T-cells that have been genetically modified to attack breast cancer cells or various immunotherapies.

They believe this method has several potential advantages including the reduction of toxicity by limiting systemic exposure of the T-cells or immunotherapy; improved efficacy by placing the T-cells or immunotherapy in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and, lymphatic migration of the CAR-T cells or immunotherapy potentially extending their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination. Their approach is in the R&D stage and is currently not FDA approved.

Expansion of Scientific Advisory Board

At the end of 2017, they added Dr. Carl Novina to our Scientific Advisory Board. Together with Dr. Jack Cuzick, they now have a world-renowned group advising on the scientific and medical aspects of their programs.

Capital Raising Activity

In 2017, they made significant improvements to their balance sheet by raising approximately $12 million in capital, which strengthened their balance sheet and improved their stockholder base with the addition of institutional biotech-focused investors.

Atossa also provided the following 2018 potential milestones:

First half of 2018 – opening the Phase 2 Study of topical Endoxifen to treat MBD at Stockholm South General Hospital in Sweden (which they plan to complete in 2018)

First half of 2018 – opening the Phase 2 Study of oral Endoxifen to treat patients who are not responding to Tamoxifen (which they plan to complete in 2018).

Second half of 2018 – commencing one or more studies to demonstrate safety and efficacy of administering TRAP CAR-T or another immunotherapy with their microcatheters.

Throughout 2018 – Identifying additional opportunities for their Endoxifen formulations; and Continuing our Phase 2 study administering Fulvestrant with their microcatheters.

Dr. Steve Quay, President and CEO, commented, “In the later part of 2017, we completed a Phase 1 Study of our proprietary oral and topical Endoxifen formulations, and we were pleased to report that all study objectives were met. We are now looking forward to opening enrollment in two Phase 2 studies.  One will use our oral Endoxifen to treat breast cancer patients who are not responding to tamoxifen.  Tamoxifen is the current FDA-approved standard of care for the approximately one million breast cancer survivors to prevent a recurrence and new cancer.  The second study will use our topical Endoxifen to determine if it can reduce a condition called mammographic breast density, or MBD.  Mammographic Breast Density is an independent risk factor for developing breast cancer.  It affects approximately 10 million women in the U.S.  We are also planning to commence an additional study with topical Endoxifen as well as a study using our intraductal microcatheters to deliver CAR-T or other immunotherapy.”

Atossa provided the following 2017 Financial Results:

Revenue and Cost of Revenue: For the years ended December 31, 2017 and 2016, they have no source of sustainable revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were $7,649,171 for the year ended December 31, 2017, which is a decrease of $319,419 or 4.0%, from the year ended December 31, 2016.  Operating expenses for 2017 consisted of general and administrative (G&A) expenses of $4,859,369, R&D expenses of $2,328,087, and impairment of their Acueity intangible assets of $461,715.

General and Administrative Expenses: G&A expenses were $4,859,369 for the year ended December 31, 2017, a decrease of $1,619,824, or 25.0% from the total G&A expenses for the year ended December 31, 2016, of $6,479,193.  G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses.  The 2017 decrease in G&A expense was primarily attributable to a reduction in payroll expenses resulting from decreased headcount, rent and exit costs incurred in 2016.  At the beginning of 2016, their strategy shifted away from the commercialization of medical devices towards focusing exclusively on the development of their pharmaceutical and microcatheter candidates.

Research and Development Expenses: R&D expenses for the year ended December 31, 2017, were $2,328,087, an increase of $1,557,660, or 202% from R&D expenses in 2016 of $770,427.  The increase in R&D expenses is attributed to salaries, manufacturing, and clinical trial expenses associated with their Endoxifen program for which manufacturing commenced at the beginning of 2017 and the clinical studies commenced in mid-2017.  They expect their R&D expenses to increase throughout 2018 as they commence Phase 2 clinical studies of Endoxifen, continue the clinical trial of fulvestrant administered via their microcatheters and as they continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via their intraductal microcatheters.

Cash and Cash Equivalents: As of December 31, 2017, the Company had approximately $7.2 million in cash and cash equivalents and working capital of approximately $6.7 million.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Announces 2017 Financial Results and Provides Company Update

SEATTLE, March 08, 2018– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announces …..

Read Full Article

Provider of Cloud Services, Fusion, Hosting Q4 & 2017 Results Conference Call Thursday, March 22

New your City-based Fusion (FSNN) is a leading provider of integrated cloud solutions to small, medium and large businesses, & is a single source for the cloud. Fusion’s advanced, proprietary cloud services platform enables the integration of leading-edge solutions in the cloud, including cloud communications, contact center, cloud connectivity, and cloud computing. Fusion’s innovative, yet proven cloud solutions lower their customers’ cost of ownership and deliver new levels of security, flexibility, scalability, and speed of deployment.

Fusion will hold a conference call on Thursday, March 22, 2018, at 10:30 a.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2017. Financial results will be issued in a press release prior to the call. Fusion CEO Matthew Rosen and CFO Michael Bauer will host the conference call, followed by a question and answer period.

To access the call, you dial Toll-free 1-888-882-4478 domestically, & the International dial-in number is 1-323-794-2149. The Conference ID is 1597159.

Michael Bauer, Fusion’s CFO, recently stated, “We are very excited to complete the Birch transaction. The combined company is projected to have approximately $575 million in pro forma annual revenue and over $150 million in pro forma annual Adjusted EBITDA, including over $20 million in expected cost synergies.” 
To learn more about Fusion (Nasdaq: FSNN) & Goldman Sachs (GS) and to track their progress please visit the Vista Partners Coverage Pages. 

Fusion Sets Fourth Quarter and Full Year 2017 Financial Results Conference Call for Thursday, March 22, 2018 at 10:30 a.m. ET

NEW YORK, March 08, 2018– Fusion, a leading provider of cloud services, will hold a conference call on Thursday, March 22, 2018 at 10:30 a.m. Eastern time to discuss its results for the fourth quarter …..

Read Full Article

HIIQ Heading To Roth Capital Growth Stock Conference in Dana Point, California March 13th

Health Insurance Innovations, Inc. (NasdaqGM: HIIQ) is a market leading cloud-based technology platform and distributor of innovative health insurance products that are affordable and meet the needs of health insurance plan shoppers. HIIQ helps develop insurance products through their relationships with best-in-class insurance companies and markets them via its broad distribution network of licensed insurance agents across the nation, its call center network and its unique online capability. HIIQ’s Consumer Division includes, a website for researching, comparing and purchasing short-term health insurance products online and, a free website that compares and ranks all health insurance plans and uses objective data to publish unbiased health insurance market analyses and other consumer advocacy research.

HIIQ announced this week that it will present at the 30th Annual Roth Capital Growth Stock Conference in Dana Point, California.  The presentation is scheduled for Tuesday, March 13, 2018, at 11:00 a.m. PDT.

Recently, HIIQ announced that it expects annual revenue for 2018 to be between $290 million and $300 million or grow approximately 15% to 20% year-over-year, adjusted EBITDA to be between $54 million and $57 million or grow approximately 20% to 25% year-over-year and adjusted EPS to be between $2.45 and $2.55 or grow approximately 48% to 55% year-over-year. These guidance numbers are based on the Company’s current method of accounting for revenue. As an emerging growth company, it will be adopting the revised revenue recognition standard, known as ASC 606, in the fourth quarter of 2018.

To learn more about HIIQ and to track its ongoing progress please visit the Vista Partners HIIQ Coverage Page.

Health Insurance Innovations, Inc. To Present at the 30th Annual Roth Capital Growth Stock Conference on March 13, 2018

TAMPA, Fla., March 07, 2018– Health Insurance Innovations, Inc., a leading cloud-based technology platform and distributor of affordable health plans, today announced that it will present at the 30th …..

Read Full Article

Vista Partners Quote of the Day (3-7-18) via Warren Buffett

“Don’t watch the market closely. If they’re trying to buy and sell stocks, and worry when they go down a little bit … and think they should maybe sell them when they go up, they’re not going to have very good results.” – Warren Buffett

Vista Partners recently published “Concerned?” Vista Partners Weekly Market Update 3-3-18 and it is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

Stay Informed! Stay Competitive! It’s FREE & EASY to sign up.



James Pitaro Appointed As New President of Disney’s ESPN

The Walt Disney Company (DIS) and its subsidiaries is a diversified worldwide entertainment company that operates in four business segments: Studio Entertainment, Media Networks, Parks and Resorts, and Consumer Products & Interactive Media.

The Walt Disney Company has announced that James Pitaro has been named the President of ESPN and the Co-Chair, Disney Media Networks. Pitaro has served as the Chairman of Disney Consumer Products and Interactive Media since 2016.

The appointment of Pitaro comes as ESPN prepares the launch of its new direct-to-consumer subscription streaming service. The provides Mr. Pitaro with a great amount of opportunity, with making transformative entertainment experiences using digital technology has been a pillar of his career thus far. Before his roles at Disney, James Pitaro has served as vice president and head of Yahoo Media, vice president of business affairs for LAUNCH Media, Inc., and practiced law at several firms in New York.

Jimmy is a talented and dedicated leader with the right strategic vision, relentless drive and passion for sports required to lead the stellar ESPN team at this incredibly dynamic time. Jimmy forged his career at the intersection of technology, sports and media, and his vast experience and keen perspective will be invaluable in taking ESPN into the future.” – Robert A. Iger, CEO of The Walt Disney Company

To learn more about The Walt Disney Company (DIS) and to continue to track its progress please visit the Vista Partners Walt Disney Company Coverage Page.

James Pitaro Named President of ESPN and Co-Chair, Disney Media Networks – The Walt Disney Company


Read Full Article